Spyre Therapeutics, Inc.

SYRE Healthcare Biotechnology

Spyre Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $886,000.00, down 62.0% from fiscal 2022. In the quarter to June 2026, EPS grew 26.5% and free cash flow fell 50.1%, each against the same quarter a year earlier.

79.90 0.20 −0.25%
Market cap
$7.4B
P/E
0.0×
Fwd P/E
−4.8×
Dividend yield
—
F-score
3/9
Altman Z
−3.82
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
18.53 8.97 13.25 10.90
Net Debt/EBITDA
27.51 16.25 13.23 8.55
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.82) (0.73) (0.70) (0.61)
Book value per Share
13.00 8.54 11.17 7.53
Free Cash Flow
(69.88) (57.37) (44.58) (37.12)
Other line items

Show all line items

Columns are period end dates